Kamada Ltd. (KMDA)
- Previous Close
5.53 - Open
5.53 - Bid --
- Ask --
- Day's Range
5.50 - 5.59 - 52 Week Range
4.08 - 6.53 - Volume
8,480 - Avg. Volume
21,734 - Market Cap (intraday)
320.161M - Beta (5Y Monthly) --
- PE Ratio (TTM)
24.22 - EPS (TTM)
0.23 - Earnings Date May 8, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.00
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
www.kamada.com378
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: KMDA
Performance Overview: KMDA
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KMDA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KMDA
Valuation Measures
Market Cap
314.77M
Enterprise Value
275.32M
Trailing P/E
24.22
Forward P/E
20.49
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.13
Price/Book (mrq)
1.30
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
8.33%
Return on Assets (ttm)
2.62%
Return on Equity (ttm)
5.91%
Revenue (ttm)
149.54M
Net Income Avi to Common (ttm)
12.46M
Diluted EPS (ttm)
0.23
Balance Sheet and Cash Flow
Total Cash (mrq)
48.19M
Total Debt/Equity (mrq)
3.55%
Levered Free Cash Flow (ttm)
-17.66M
Research Analysis: KMDA
Company Insights: KMDA
KMDA does not have Company Insights